Company: PCRX
Filing Date: 2025-03-14
Form Type: DFAN14A
Source: 0000921895-25-000772
Chunk: 0

Company: Pacira BioSciences, Inc.
Filing Date: 2025-03-14
Form: DFAN14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

(Amendment No. )</div>

Filed by the Registrant ☐

Filed by a Party other than the Registrant ☒

Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☒ | Soliciting Material Under § 240.14a-12 |

| PACIRA BIOSCIENCES, INC.                                                  |
| (Name of Registrant as Specified In Its Charter)                          |
| DOMA PERPETUAL CAPITAL MANAGEMENT LLC                                     
 DOMA PERPETUAL LO EQUITY MAASTER FUND LP                                  
 DOMA PERPETUAL PARTNERS GP LLC                                            
 PEDRO ESCUDERO                                                            
 JOSEPH KROMHOLZ                                                           
 PHILIP PUCCIARELLI                                                        
 ERIC DE ARMAS                                                             |
| (Name of Persons(s) Filing Proxy Statement, if other than the Registrant) |

Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required |

| ☐ | Fee paid previously with preliminary materials |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

DOMA Perpetual Capital
Management LLC, a Delaware limited liability company, together with the other participants named herein (collectively, “DOMA”),
intends to file a preliminary proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission
(“SEC”) to be used to solicit votes for the election of its slate of director nominees at the 2025 annual meeting of stockholders
(the “Annual Meeting”) of Pacira BioSciences, Inc., a Delaware corporation (the “Company”).

On March 14, 2025, DOMA
issued the following press release:

<div align='center'>DOMA Perpetual Nominates Three Highly Qualified Candidates